Medicina y salud
Disciplina temática
National and Kapodistrian University of Athens
Atenas, GreciaPublicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (196)
2024
-
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
United European Gastroenterology Journal
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Blood Advances, Vol. 8, Núm. 2, pp. 388-398
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Dietary intake of vitamin C and gastric cancer: a pooled analysis within the Stomach cancer Pooling (StoP) Project
Gastric Cancer, Vol. 27, Núm. 3, pp. 461-472
-
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial
JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335
-
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
European Journal of Haematology
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322
-
Reproductive factors, hormonal interventions, and gastric cancer risk in the Stomach cancer Pooling (StoP) Project
Cancer Causes and Control, Vol. 35, Núm. 4, pp. 727-737
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
-
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 2, pp. e40-e49.e3
2023
-
Adult height and risk of gastric cancer: A pooled analysis within the Stomach cancer Pooling Project
European Journal of Cancer Prevention, Vol. 32, Núm. 3, pp. 215-221
-
Association of Endovascular Thrombectomy vs Medical Management with Functional and Safety Outcomes in Patients Treated beyond 24 Hours of Last Known Well: The SELECT Late Study
JAMA Neurology, Vol. 80, Núm. 2, pp. 172-182
-
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696
-
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 14, pp. 2607-2616
-
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
Leukemia, Vol. 37, Núm. 2, pp. 388-395
-
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
Frontiers in Oncology, Vol. 13
-
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748
-
Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol
Contemporary Clinical Trials, Vol. 134
-
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood, Vol. 141, Núm. 6, pp. 579-591